New York State Common Retirement Fund Decreases Stock Holdings in ADMA Biologics Inc $ADMA

New York State Common Retirement Fund reduced its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 63.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 114,504 shares of the biotechnology company’s stock after selling 198,337 shares during the period. New York State Common Retirement Fund’s holdings in ADMA Biologics were worth $1,679,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Kornitzer Capital Management Inc. KS grew its position in shares of ADMA Biologics by 652.0% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 359,985 shares of the biotechnology company’s stock worth $5,277,000 after buying an additional 312,115 shares during the last quarter. PFG Investments LLC boosted its holdings in ADMA Biologics by 2.8% in the third quarter. PFG Investments LLC now owns 221,515 shares of the biotechnology company’s stock valued at $3,247,000 after acquiring an additional 6,025 shares in the last quarter. Y Intercept Hong Kong Ltd boosted its holdings in ADMA Biologics by 40.6% in the third quarter. Y Intercept Hong Kong Ltd now owns 105,283 shares of the biotechnology company’s stock valued at $1,543,000 after acquiring an additional 30,392 shares in the last quarter. Huntleigh Advisors Inc. increased its position in ADMA Biologics by 4.2% during the 3rd quarter. Huntleigh Advisors Inc. now owns 118,588 shares of the biotechnology company’s stock valued at $1,739,000 after purchasing an additional 4,816 shares during the period. Finally, NorthCrest Asset Manangement LLC raised its holdings in ADMA Biologics by 44.3% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 19,896 shares of the biotechnology company’s stock worth $278,000 after purchasing an additional 6,109 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Up 3.1%

Shares of ADMA Biologics stock opened at $16.43 on Monday. ADMA Biologics Inc has a 1 year low of $13.50 and a 1 year high of $25.67. The firm has a market cap of $3.91 billion, a price-to-earnings ratio of 19.10 and a beta of 0.49. The company has a 50-day moving average of $18.35 and a 200 day moving average of $17.02. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.13 and a quick ratio of 3.65.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, ADMA Biologics currently has an average rating of “Buy” and an average price target of $28.50.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.